Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Erfan Nadji

Ophthalmology Santa Monica, CA Medical Doctor

NPI 1376876235 CMS profile 886083

1301 20Th Street, Suite 260, Santa Monica, CA 90404

Open in the dashboard

General payments

$5,599

181 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erfan Nadji of Santa Monica, CA is reported in the CMS Open Payments database as having received $5,599 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,134 37
2024 General $592 26
2023 General $1,228 20
2022 General $713 21
2021 General $736 33
2020 General $473 20
2019 General $723 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erfan Nadji
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Erfan Nadji were reported at $1,134. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Erfan Nadji Ophthalmology median Middle half National median
2019 $723 $258 $104–$655 $163
2020 $473 $126 $45–$321 $114
2021 $736 $205 $76–$534 $132
2022 $713 $266 $100–$678 $149
2023 $1,228 $308 $117–$745 $160
2024 $592 $340 $127–$846 $164
2025 $1,134 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Glaukos Corporation $1,138 11 payments
  2. Alcon Vision LLC $918 21 payments
  3. Tarsus Pharmaceuticals, Inc. $511 18 payments
  4. Johnson & Johnson Surgical Vision, Inc. $427 5 payments
  5. Allergan Inc. $334 25 payments
  6. Bausch & Lomb Americas Inc. $330 16 payments
  7. Dompe US, Inc. $243 8 payments
  8. AbbVie, Inc. $187 9 payments
  9. Carl Zeiss Meditec USA, Inc. $177 1 payment
  10. Kala Pharmaceuticals, Inc. $160 13 payments
  11. Other $1,175 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,383 176 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $100 1 payment
  3. Travel and Lodging $62 1 payment
  4. Gift $37 2 payments
  5. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. XDEMVY $511 18 payments
  2. iStent infinite Trabecular Micro-Bypass System Model iS3 $428 3 payments
  3. Tecnis Symphony IOL $382 2 payments
  4. Tecnis Symphony Toric IOL $382 2 payments
  5. Tecnis 3-piece IOL $382 2 payments
  6. Tecnis 1-piece IOL $382 2 payments
  7. HYDRUS Microstent $352 11 payments
  8. VYZULTA $267 10 payments
  9. iStent inject W $262 3 payments
  10. OXERVATE $243 8 payments
  11. Other $3,650 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,588

Median for Ophthalmology: 891

Drug cost

$487,723

Median for Ophthalmology: $68,233

Branded share of claims

46%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 144 $117,820
Xdemvy Lotilaner Brand 57 $105,410
Xiidra Lifitegrast Brand 58 $43,306
Miebo Perfluorohexyloctane/Pf Brand 46 $33,820
Lumigan Bimatoprost Brand 55 $31,279
Combigan Brimonidine Tartrate/Timolol Brand 73 $18,765
Vyzulta Latanoprostene Bunod Brand 42 $18,626
Prolensa Bromfenac Sodium Brand 43 $14,668
Cyclosporine Generic 42 $13,495
Prednisolone Acetate Generic 293 $13,042

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$611,578

Of which drugs: $11

Medicare patients

1,988

Average age 77

Services billed

9,265

1,242 women, 746 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 50%
Ischemic heart disease 35%
Osteoporosis 27%
Diabetes 24%
Cancer 18%
Atrial fibrillation 16%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 14 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $179
$179 57 —
VYZULTA
  • Bausch & Lomb Americas Inc. $174
$174 42 —
OXERVATE
  • Dompe US, Inc. $88
$88 — —
IYUZEH
  • Thea Pharma Inc. $59
$59 — —
MIEBO
  • Bausch & Lomb Americas Inc. $46
$46 46 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record